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Head and neck cancer (HNC) is a
major health problem in Brazil as well
as in other countries. In the U.S., the
annual incidence is about 50,000 new
cases/year, and a total of 500,000 will
be diagnosed worldwide. Unfortu-
nately, most of the cases are diagnosed
in advanced stages of the disease (60%
stages III and IV) and are squamous
cell carcinoma. Risk factors for HNC
are well established, smoking and al-
cohol consumption being the most im-
portant and studied. Recently, the im-
portance of new risk factors such as the
Epstein-Barr virus and human papil-
loma virus have received more atten-
tion, especially regarding nasopharyn-
geal and laryngeal carcinoma, respec-
tively.
In spite of the high prevalence of
this disease, studies including radio-
therapy and chemotherapy in HNC
have been subject to many technical
problems. The difficulty is attributed
at least in part to patient-related prob-
lems, such as co-morbidities (due in
part to smoking and alcohol consump-
tion), advanced stage of the disease at
diagnosis, and the necessity of a
multidisciplinary approach including
surgery, medical oncology, radio-
therapy, nutrition, and speech pathol-
ogy. In the past few years, some
progress has been made in trying to
address the importance of protocols
involving chemotherapy and radio-
therapy for irresecable disease and for
organ-preservation strategies.
Randomized studies such as those
presented by Brizel1, Wendt2, and
Merlano3 clearly demonstrate the ben-
efit of combining chemotherapy with
radiotherapy versus radiotherapy alone
for locally advanced HNC; these stud-
ies involved patients with all sites of
HNC. Studies from Calais4,5 and Al-
Sarraf6 confirmed the superiority of
combined strategy for specific sites
like the oropharynx and nasopharynx,
respectively. Although all these stud-
ies reported better locoregional con-
trol, and some of them reported sur-
vival benefits, unfortunately, toxicity
was a limiting factor in most of them.
For organ-preservation purposes,
the study run by the Veterans Affair
Study Group7 (VA) with more than 300
patients, comparing sequential treat-
ment with 5-fluorouracil/cisplatin fol-
lowed by radiotherapy (for those who
responded to 2 cycles of induction
therapy) with standard laryngectomy
followed by radiation, showed no ben-
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efit in terms of survival, but the larynx
was preserved in 60% of the patients
at the 5-year follow-up. These results
were confirmed in a phase III study in
hypopharynx tumors run by the East-
ern Oncology Group (ECOG)8.
A recent meta-analysis was pre-
sented by Pignon9, analyzing studies
with chemotherapy and radiation. This
meta-analysis and another by El-
Sayed10 confirmed the benefit in terms
of survival for the use of chemotherapy
and radiation in a concomitant fashion;
the benefit in terms of survival was 8%
compared to 4% for the sequential treat-
ment studies (chemotherapy before ra-
diation); adjuvant studies with chemo-
therapy alone after surgery did not
show benefit in these analysis.
Another important study was pre-
sented by Forastiere11 at the American
Congress of Clinical Oncology in
2001, comparing radiotherapy alone
versus the VA regimen versus concomi-
tant therapy with cisplatin (100 mg/m2
every 3 weeks) and radiation. This
study also demonstrated the superior
outcome for the concurrent radioche-
motherapy compared to radiation-only
treatment (larynx preserved at 5 years,
85% vs. 64%, and 2-year laryngectomy
free-survival 68% vs. 53%).
Our results with concomitant
therapy using the same regimen for
oropharyngeal and laryngeal tumors
were recently presented (Proceedings
of ASCO meeting 2003, in press) and
confirmed 40% complete responses,
although 40% of the patients were not
able to complete the 3 cycles of
planned chemotherapy.
New directions in the treatment of
HNC can be summarized in the follow-
ing topics:
1. advances in radiation treatment
2. new combinations
3. target / molecular therapy and new
molecular markers
4. re-irradiation and concurrent che-
motherapy
5. use of new radiology techniques
1.  ADVANCES  IN  RADIATION
TREATMENT
Changes in fractionation scheme
Some of the critics who rely on the
randomized studies in HNC combining
chemotherapy and radiation are con-
cerned with the possibility of techni-
cal differences including total dose
and fractionation between the studies.
The standard therapy for gross dis-
ease is 70 Gy over 7 weeks of therapy
(1.8 to 2 Gy/fraction). Studies evalu-
ating hyperfractionation (more than 1
fraction a day) have been presented
over the last 5 years. These regimens
allowed an increase in total dose to
about 80 Gy without increase in com-
plications.
An overview reported significantly
improved local and regional tumor
control, and 3 of 4 studies reported im-
proved survival using hyperfrac-
tionation vs. standard treatment12.
Dr. Calais4,5 published the results of
a phase III randomized study of oro-
pharynx tumors comparing hyperfrac-
tionated radiation alone vs. the same
regimen with chemotherapy (cisplatin/
5-FU), and demonstrated the feasibil-
ity of the combination and the benefit
of adding chemotherapy to this radia-
tion scheme.
Another strategy with altered frac-
tionation involves delivery of radia-
tion over a short time interval. The ra-
tional for this approach is that there is
an accelerated tumor re-population by
surviving clonogenic cells at the lat-
ter phase of the therapy; this is associ-
ated with lower tumor control rates
when the therapy is lengthened.
Accelerated fractionated radiation
improves local control, but also in-
creases acute toxic effects, especially
mucositis. Such a regimen was recently
shown to improve locoregional con-
trol in head and neck cancer compared
with standard radiation treatment in a
large study done by the RTOG13.
A recent randomized study was
presented comparing accelerated ra-
diation vs. standard radiation plus
chemotherapy14. This study did not
show benefit in terms of survival and
locoregional control for the combina-
tion in a short follow-up, suggesting
that the intensified radiation could be
a new standard; the question of what
would be the result for the combina-
tion of accelerated radiation and
chemotherapy remains open.
Radiation induced toxicity
Some attempts are ongoing to de-
velop strategies that minimize radia-
tion toxicities.
Amifostine is actually the only ra-
dioprotective agent available and has
been studied in phase II and also a
phase III study conducted by Dr.
Brizel15. There is still a conflict regard-
ing the utility of this drug in reducing
xerostomia, mucositis, and dermatitis
caused by radiation. Dr. Brizel showed
in his study a significant statistical ben-
efit in terms of xerostomia and a small
nonsignificant benefit in terms of mu-
cositis, without evidence of protecting
the tumor; additionally, the time re-
quired to develop serious mucositis and
xerostomia was longer. Although some
in vitro studies have suggested that
amifostine could also protect the tumor
from the effect of radiation, neither the
phase II nor the phase III studies
showed a detrimental effect of ami-
fostine in terms of response or survival.
Based on these results, amifostine
should be reserved for situations where
the risk of toxicity and the area of ra-
diation is very high (parotid or salivary
glands); for that use, the authors recom-
mend subcutaneous administration be-
fore each radiation dose.
Another strategy that has recently
been studied is intensity-modulated
radiotherapy, which allows a compu-
terized optimization of the intensity of
multiple beams. This method enables
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the desired radiation dose to encom-
pass the targets, while avoiding the
major salivary glands and other struc-
tures at risk. Results from previous
studies confirmed that 70% of parotid
gland salivary flow could be pre-
served, and with potential for im-
proved irradiation of the tumor targets,
this strategy has been studied more fre-
quently for nasopharyngeal tumors16.
2. NEW COMBINATIONS
With the advent of new chemo-
therapy drugs, novel combinations
have been tested in HNC. Some of the
most promising agents are paclitaxel,
docetaxel, ifosfamide, gemcitabine,
and Navelbine.
Gemcitabine is approved for ad-
vanced NSCLC and pancreatic cancer.
When used alone or even with
cisplatin, it showed only moderate ac-
tivity in metastatic SCCHN. The inter-
est in this agent was higher because of
its potential as a radiosensitizer.
Our group tested gemcitabine in a
phase I study in very low doses with
cisplatin and radiation for 7 weeks in
stage IV SCCHN. After evaluating 12
patients, we confirmed previous stud-
ies that showed a high degree of ac-
tivity but with a prohibitive toxic-
ity17,18.
Paclitaxel is another promising
agent and was tested in large phase II
and III studies. In a phase III study
comparing paclitaxel/cisplatin with
cisplatin/5-FU, the results showed no
differences in response rates or sur-
vival, but the combination with
paclitaxel was superior in the quality-
of-life analysis. Two studies using the
combination of induction therapy with
paclitaxel and carboplatin were re-
cently presented19,20; these trials from
Chicago19 and Philadelphia20 used dif-
ferent schedules of the combination,
but both showed a high degree of
clinical and pathological responses,
including complete responses. Of
note, organ preservation was a fre-
quently achieved outcome.
Docetaxel has been tested in differ-
ent combinations, with radiation, or as
an induction therapy before sur-
gery21,22,23. One of the most active regi-
mens combines docetaxel with cisplatin
(with or without 5-FU)23. Despite the
potential hematological toxicity of this
regimen, phase II studies report more
than 90% responses and 40% to 60%
complete response as induction therapy.
A phase III randomized study compar-
ing docetaxel and cisplatin vs. cisplatin
and 5-FU for recurrent or metastatic
SCCHN is now on its final accrual, and
results will be available soon.
It is important to mention that al-
though the sequential regimens did not
show survival benefit, it is not yet
known whether these new regimens
that appear to have higher response
rates in phase II trials will demonstrate
a different outcome. Most of those
studies present not only with an induc-
tion treatment, but an induction fol-
lowed by concurrent chemotherapy
and radiation (usually weekly chemo-
therapy only as a radiosensitizer).
These trials offered intensive systemic
therapy, aggressive locoregional treat-
ment, and focused surgery. It will be
difficult to choose from several new
chemotherapy regimens—cisplatin/5-
FU, paclitaxel/carbo bolus, or weekly
docetaxel/cisplatin with or without 5-
FU—which is the best as induction or
concomitant therapy. Only large phase
III trials will be able to build on the
foundation of the current phase II tri-
als. These trials will also have to as-
sess toxicity, quality of life, costs, and
especially the survival benefit of the
regimen.
Our experience confirmed the dif-
ficulty of administering combined
therapy with cisplatin 100 mg/m2 and
radiation to patients with locally ad-
vanced larynx and oropharynx cancer,
even with the selection of performance
status 0 and 1 patients; the toxicity is
very high, and results are worst with
more advanced disease (stage IVb)24.
This combination should be consid-
ered the standard treatment for organ
preservation protocols until the com-
pletion of the ongoing phase III stud-
ies. We recommend that this therapy
only be given in institutions with ex-
perience in treating this disease and
with a complete multi-disciplinary
team.
3. TARGET / MOLECULAR
THERAPY AND NEW
MOLECULAR MARKERS
The last 20 years of basic research
in the mechanisms of cancer develop-
ment and progression have revealed a
number of potential therapeutic tar-
gets25. This work has culminated in the
generation of a number of novel mo-
lecular targeted agents. These agents
are important not only for increasing
clinical responses, but primarily for
providing better prognostic indicators
of patient survival or even for select-
ing the best treatment based on the
molecular analysis of the tumor.
EGFR
The single most important molecu-
lar target for SCCHN has been the epi-
dermal growth factor receptor (EGFR),
which is overexpressed in 40% to 90%
of the patients26. Epidermal growth
factor receptor is a member of the
ERBb family of tyrosine-kinase (tk)
receptors found on the cell surface. It
is overexpressed on the majority of
SCCHN, and it appears to be an early
event in carcinogenesis. Activation of
EGFR is related to cell proliferation,
protection from apoptosis, and produc-
tion of proinflammatory cytokines.
Two principal methods for inhibit-
ing EGFR have been identified and
studied in clinical trials: antibodies to
EGFR and small molecules that inhibit
the enzymatic function of the receptor
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by binding to intracellular tyrosine ki-
nase.
Cetuximab (c225) is the most stud-
ied antibody and has engendered a lot
of controversy. Single agent activity of
the antibody is marginal; however, a
lot of interest came from combination
with cisplatin and especially with ra-
diation. Three trials of cetuximab and
cisplatin were presented at the 2002
American Oncology Meeting
(ASCO)27,28,29; activity was suggested
with this combination in patients con-
sidered refractory to previous cisplatin
chemotherapy. A trial presented by Dr.
Baselga had a 14% response rate after
progression on platin-based regimens.
The Eastern Cooperative Oncology
Group is now completing a phase III
trial with cisplatin and cetuximab or
placebo; yearly results suggest higher
response rates without disease-free sur-
vival difference.
Robert et al.30 presented in a phase
I trial the interaction of cetuximab
with radiation and showed that this
combination was very effective (100%
response rate) as a radiosensitizer with-
out excessive toxicity, which was al-
ready suggested by in vivo studies. A
randomized trial has recently ended
accrual.
Two small molecules known as
gefitinib (ZD 1839) and OZI-774 also
have been evaluated in SCCHN. A
phase I study showed some activity, and
a phase II study was presented in the
2002 ASCO meeting31. A total of 52 pa-
tients with recurrent or metastatic
SCCHN (mostly treated with chemo-
therapy) were treated with ZD 1839 500
mg orally, and there was a surprisingly
20% response in 40 available patients.
In a large phase II study presented
by Senzer32 with 124 patients, the re-
sponse rate to OZI-774 was 5.6% (par-
tial response) and 39% stable disease;
this was not associated with EGFR sta-
tus. Our group is now starting a phase
II trial of OZI-774 concurrent with
cisplatin 100 mg/m2 weekly for 3
weeks and radiation (70 Gy) for lo-
cally advanced SCCHN.
Reasons for the enthusiasm in test-
ing these compounds are related to the
possibility of oral use (OZI-774 and
ZD 1839) and the lower incidence of
toxicity, mostly skin rash and mild
diarrhea, as well as the molecular
mechanism of action that allows future
combination with chemotherapy.
Gene therapy
Virus-based therapy for HNC has
been evolving for some time. Results
have been published with onyx-015,
adp53, and others33,34. Unfortunately, it
is still not known how to best use these
therapies, which are still reserved for
a small group of patients who can re-
ceive therapy as an intratumoral injec-
tion. A study of gene therapy in com-
bination with radiation and another
phase III study comparing gene thera-
py with chemotherapy for recurrent
disease are ongoing.
Molecular/genetic markers
p53. In head and neck cancers, p53
mutations are present in 33% to 59%
of tumors as determined by PCR, loss
of heterozygosity occurs in 38%, and
abnormal immunohistochemical stain-
ing occurs in 37% to 76% of tumors35.
There is a lot of controversy regarding
the status of p53 as a marker for prog-
nosis and survival; this could reflect a
methodology problem or the small
number of patients in some studies.
Studies evaluating the adequacy of
surgical margins showed that in pa-
tients with histologically and genetic
negative margins (p53 negative in the
margin), the incidence of recurrence is
lower than when the p53 is mutated in
the margin (genetically positive)36. At
the moment, p53 mutations should not
be considered as a predictor of sur-
vival or used to select patients for dif-
ferent treatments
EGFR. Besides the high percentage
of overexpression of this marker (40%
to 90%) and the potential for target
treatments directed to block this
receptor, there are only a few studies
that suggest that patients with overex-
pression have worse survival. In a re-
cent study presented by Bensadourn et
al.37 with 92 patients who underwent
hyperfractionated radiation and che-
motherapy, overexpression of EGFR
was a major prognostic factor in
univariate and multivariate analysis.
p16/p21/p27. These are tumor sup-
pressor genes that act to modulate cell
proliferation. Abnormalities of these
genes are frequent in SCCHN and had
been related to worse survival, in-
creased recurrences, tumor progression,
and nodal metastasis in some studies.
4. RE-IRRADIATION AND
CONCURRENT
CHEMOTHERAPY
Re-irradiation with concurrent
chemotherapy is a new approach that
has been increasingly studied in re-
cent years; this is based on the high
rate of locoregional recurrences in pre-
viously irradiated sites and secondary
primary head and neck cancers. The
standard of care of previously irradi-
ated nonresectable recurrent head and
neck cancer has been chemotherapy
alone; however, chemotherapy alone
results in limited palliation with no
long-term survivors (response rates
10% to 50% and a median survival
time of 6 months).
It must be assumed that the major-
ity of tumors that recur after radiation
have arisen from selected resistant
cells. Therefore, re-irradiation alone,
especially with low doses, is not likely
to be effective. This approach is con-
sidered to be a potentially curative op-
tion for recurrent nonresectable disease
arising in irradiated areas. Results from
several centers reveal varying out-
comes, with 5-year survival ranging
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from 9% to 93% in selected series38,42.
The differences could be attributed to
variations in patient selection,
anatomic sites, radiation dosages, and
concurrent chemotherapy.
A recent series from the University
of Chicago39,40 included patients
treated with 5-fluorouracil, and hy-
droxyurea concomitant with twice-
daily re-irradiation consisting of 1.5
Gy bid to a total dose of 75 Gy (60 Gy
in previous treatment with optimal sur-
gical debulking). Treatment was given
in alternating weeks (5 days followed
by a 9–day break). With a median fol-
low-up of 48 months, the 3-year sur-
vival and locoregional control were
29% and 42% respectively.
The radiation therapy oncology
group (RTOG) reported the results of
86 patients treated with alternating
weeks of hyperfractionated radio-
therapy and concomitant chemo-
therapy (with 5-FU and hydroxyurea).
With a total dose of radiation of 60 Gy
and a follow-up of only 16 months,
the 1-year and 2-year survival were
42% and 16%, respectively. A new
RTOG protocol 99-11 is now accruing
patients to a regimen consisting of
paclitaxel and cisplatin with split-
course hyperfractionated radiotherapy.
There are several prognostic factors
that influence the results of the re-ir-
radiation protocols. The first is the pos-
sibility of optimal surgical debulking
before treatment, as shown by the work
of Haraf et al. who reported that opti-
mal debulking was significantly pre-
dictive of freedom from progression at
any site and freedom from locore-
gional progression. The second is the
anatomic site, since reported outcomes
seen in patients with recurrent na-
sopharynx and laryngeal carcinoma
seemed encouraging in selected series.
Third is the time interval, since prior
irradiation and re-irradiation dose are
also strong predictors of outcome. A
study from Spencer et al.41 suggested
that time to re-irradation greater than
24 months was predictive of longer
median survival (15 months) com-
pared to re-irradiation within 1 year
(ms 6.5 months). Arguments for high-
dose re-irradiation are based on the
probability of the presence of ra-
dio-resistant cells that recurred after
previous therapy. Most of the studies
showed that re-irradiation with doses
greater than 58 Gy were related to
longer survival41.
It is important to emphasize that re-
irradiation must be undertaken in in-
stitutions with experience in dealing
with these patients and with a
multidisciplinary team, since toxicity
to skin, mucous membranes, and blood
cells, as well as death related to treat-
ment have been reported in most of the
series.
5. USE OF NEW RADIOLOGY
TECHNIQUES
One of the recurring problems in
dealing with SCCHN is the difficulty
in evaluating the response after treat-
ment with chemotherapy and radia-
tion.
The PET scan (positron emission
tomography) is being considered a
new tool for HNC diagnosis, staging,
and also restaging of head and neck
cancers43,44. In cases of unknown pri-
mary tumors of the head and neck, PET
is able to identify 20% to 40% of the
cases; in tumor staging, the reported
sensitivity and specificity are 83% and
93%, respectively. Since local recur-
rences are very common in this disease,
PET has also been used to evaluate re-
sidual disease as well as recurrence in
the neck. In a study by Lindholm et
al.44, PET was used before and after ra-
diotherapy and was related to com-
plete responses after irradiation.
Radiochemotherapy after surgery
Studies including adjuvant treat-
ment after surgery are, at the moment,
not conclusive. Two important studies
were recently presented showing a
possible advantage of using radiation
and chemotherapy in high-risk pa-
tients after surgery. The first study by
Cooper et al.45 in 228 patients consid-
ered high-risk after surgery (T3-4 or
N2-3 or extracapsular disease or posi-
tive margins), were randomized be-
tween radiotherapy (66 Gy) or radio-
therapy plus cisplatin 100 mg/m2
every 3 weeks. The preliminary analy-
sis demonstrated no improvement in
locoregional control or survival, but
disease-free survival was better for
combined treatment, and toxicity was
also very high. In a similar study run
by the EORTC46 with 334 patients, the
combined therapy had higher local
control, disease-free survival, and over-
all survival, with no excessive toxic-
ity. The difference in results could be
explained by the number of patients,
selection of patients, or short follow-
up, but definitive conclusions are not
possible at this moment. Since both tri-
als showed at least an increase in dis-
ease-free survival, radiochemotherapy
could be an option for high-risk pa-
tients with a younger age and good
performance status.
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RESUMO
revisão dos avanços que vêm ocorren-
do no tratamento não cirúrgico do cân-
cer de cabeça e pescoço, com especial
atenção à diferentes protocolos de ra-
dioterapia, novas combinações de
quimioterapia, terapia e marcadores
moleculares bem como a incorporação
de terapia de re-irradiação e tratamen-
to adjuvante após cirurgia.
DESCRITORES: Quimioterapia.
Radioterapia. Câncer de cabeça e
pescoço.
HERCHENHORN D e col. - Avanços
no tratamento quimioterápico e
radioterápico do Câncer de cabeça
e pescoço. Rev. Hosp. Clín. Fac.
Med. S. Paulo 59(1):39-46, 2004.
Novos avanços vêm sendo incor-
porados no tratamento radio e quimio-
terápico do Câncer Epidermóide de
Cabeça e Pescoço. Apesar do prognós-
tico reservado dos tumores avançados,
não devemos esquecer da possibilida-
de de incorporarmos protocolos com-
binados de quimioterapia e radiotera-
pia com intuito de preservação de ór-
gãos ou paliação em estágios de do-
ença recorrente ou localmente avança-
da que não são bons candidatos à ci-
rurgia. Nesse contexto, há uma neces-
sidade urgente de incorporar questio-
nários de qualidade de vida e avalia-
ção funcional nos estudos de preserva-
ção de órgãos, além de assegurar a im-
portância do resgate cirúrgico depois
de protocolos radio-quimioterápicos.
Os autores realizam uma extensa
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